The study aimed at assessing current direct costs of 1-year implantable cardioverter defibrillator (ICD) follow-up based on Remote Monitoring system compared with conventional quarterly in-hospital traditional follow-ups, considering all direct costs burdened on patients and hospital. Patients (N = 233) with indications for ICD were consecutively recruited in two homogeneous population and randomized at implant to be followed-up for 12 ± 3 months. Direct Costs were calculated distinguishing between provider and patient costs, through an ABC estimation made by empirical observation and direct surveys. Moving from the traditional cost accounting rules, it was estimate that direct costs were significantly reduced in the RM group; any patient could save about € 156/year while the hospital could save about € 20 per patient/year.
Keywords: Cost-analysis, telemedicine, remote monitoring (RM), implantable cardioverter defibrillator (ICD), health technology assessment, health care management.